poisar

Stocks · News reference

Why is Aclaris Therapeutics Stock Trading Lower on Monday?

BenzingaVandana Singh

Aclaris Therapeutics misses Phase 2 bosakitug endpoints but launches its Phase 2b modzatinib trial for moderate-to-severe lichen planus.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading